At the origin of peripheral arterial disease: The role of endothelin in endothelial dysfunction;En el origen de la enfermedad arterial periférica: Papel de la endotelina en la disfunción endotelial

Angiologia

Volumn 60, Issue 6, 2008, Pages 395-401

  Flórez González, Aurora ^a   De Haro Miralles, J ^a   Varela Casariego, C ^a   Acin F ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Endothelial dysfunction; Endothelin; Inflammation; Intermittent claudication; Ischaemia; Peripheral arterial disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN;

AGED; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTERY DISEASE; ARTICLE; BLOOD LEVEL; BRACHIAL ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; ISCHEMIA; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

EID: 60749101183     PISSN: 00033170     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-3170(08)06002-1     Document Type: Article

References (20)

1. Healy B. Endothelial cell dysfunction: an emerging endocrinopathy linked to the coronary disease. J Am Coll Cardiol 1990; 16: 357-8.
2. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet 2001; 358: 946-8.
3. Dubin D, Pratt RE, Cooke JP, DzauVJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol 1989; 1: 150-4.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
5. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16: 1081-98.
6. Uchida Y, Nomiya H, Saotome M, Nomura A, Ohtsuka M, Yanagisawa M, et al. Endothelin, a novel vasoconstrictor peptide, as a potent bronchoconstrictor. Eur J Pharma 1998; 154: 227-8.
7. Inoue A, Yanagisawa M, Kimura S, Kasuya S, Kasuya Y, Miyauchi T, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86: 2863-7.
8. Medina F, De Haro J, Martínez E, Flórez A, March JR, Acín F. Relación de la dilatación de la arteria braquial mediada por flujo y el índice tobillo-brazo en pacientes con enfermedad arterial periférica. Angiologia 2007; 59: 55-61.
9. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; Suppl 3: S27-32.
10. De Haro J, Medina F, Martínez E, Flórez A, Varela C, Acín F. Relación del tamaño del aneurisma de aorta abdominal asintomático con los niveles plasmáticos de proteína C reactiva. Angiologia 2007; 59: 111-20.
11. Lüscher T, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-40.
12. Medina FJ, De Haro J, March JR, Martínez E, López-Quintana A, Acín F. Relationship between non-invasively measured endothelial function and peripheral arterial disease. Angiology 2008 [in press].
13. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990; 172: 1741-8.
14. Omland T, Lie RT, Aakuaag A, Aarsland T, Dickstein K. Plas ma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
15. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cells proliferation via an external autocrine loop. J Biol Chem 1994; 269: 1012-8.
16. López Farre A, Riesco A, Espinosa G, Diqiuni E, Cernadas MR, Álvarez V, et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993; 88: 1166-71.
17. Lerman A, Holmes D, Bell M. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 92: 2426-31.
18. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
19. Clavell AL, Mattingly MT, Stevens TL, Nir A, Wright S, Aarhus LL, et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996; 97: 1286-92.
20. Hernández-Perera O, Pérez-Sala D, Navarro J, Sánchez-Pascuala R, Hernández G, Díaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.